Rescue medications clinical trials
8 indexed studies · 5 currently recruiting
- Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
This study compares a new medicine, sacituzumab tirumotecan, with standard chemotherapy for endometrial cancer. It's for people whose cancer has returned or progressed after previous treatments (platinum-based chemotherapy and immunotherapy). Researchers want to see if the new medicine helps people live longer and keeps the cancer from getting worse.
For: Endometrial CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
This study is for women with cervical cancer that has spread. It's testing new combinations of medicines (sac-TMT, pembrolizumab, and possibly bevacizumab) to see if they are safe and can help people live longer or stop their cancer from getting worse.
For: Cervical CancerUnited States · Argentina · Austria - Active not recruitingPHASE3
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
This study looks at a new medicine, sacituzumab tirumotecan, for advanced stomach or oesophagus cancer. It compares this new medicine to standard treatments to see if it's safer and works better for patients who have already had other treatments.
For: Gastroesophageal CancerUnited States · Belgium · Brazil - RecruitingPHASE3
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
This study is for women with advanced ovarian cancer that has responded well to initial treatment. It's testing a new medicine called sac-TMT, sometimes with bevacizumab, to see if it can keep the cancer from growing or coming back for longer than standard care.
For: Ovarian Neoplasms · Ovarian CancerUnited States · Argentina · Australia - RecruitingPHASE2
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
This study is looking for new treatments for advanced squamous non-small cell lung cancer that hasn't responded to usual treatments. Researchers are testing new medicines called antibody drug conjugates (ADCs) to see if they can shrink the cancer and if they are safe.
For: Lung NeoplasmUnited States · Chile · China - RecruitingPHASE1, PHASE2
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
This study looks at new treatments for advanced stomach or gullet cancer that has already been treated once. It compares different drug combinations to see how safe and effective they are for patients whose cancer has come back or spread.
For: Gastroesophageal Junction · Gastroesophageal Adenocarcinoma · Esophageal NeoplasmsUnited States · Brazil · Chile - RecruitingPHASE2
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
This study is testing a new medicine, MK-5684, for breast, ovarian, and endometrial cancers. It aims to see if MK-5684, which blocks steroid hormones, can stop cancer from growing or spreading for longer than current standard treatments.
For: Malignant NeoplasmUnited States · Argentina · Brazil - Active not recruitingPHASE1
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
This study is testing a new medicine, MK-6837, by itself and with another drug, pembrolizumab. It's for people with advanced cancers that haven't responded to usual treatments. The main goals are to check its safety and how well people tolerate it.
For: Neoplasm MetastasisUnited States · Australia · Canada